Jazz Pharmaceuticals stock soars 50% as sleep disorder drugs fuel growth
Jazz Pharmaceuticals, a biopharma firm specialising in neuroscience and oncology, has seen its stock climb nearly 50% in the past year. The company, valued at $11.64 billion, remains a strong player in the market with its flagship sleep disorder treatments, Xywav and Xyrem, driving revenue. The stock reached an all-time high of $198.00 on 1 February 2024, boosted by a 15.5% surge that month. Positive momentum in the biotech sector and strong earnings results—beating revenue and earnings-per-share expectations—helped push the price upward. Since then, the stock has dipped slightly, trading around $185 in early 2026, with technical support holding near $186.92.
Analysts remain optimistic, forecasting a potential new peak in 2026. Projections suggest a 175% increase in EBITDA by that year, reinforcing bullish sentiment. Wall Street reflects this confidence, with multiple 'Strong Buy' ratings and a 100% 'Buy' consensus from technical analysts. The company's Weighted Alpha of +55.55 further signals strong performance over the past year. The firm's growth aligns with broader trends in the biopharma industry, where demand for specialised treatments continues to rise. Xywav and Xyrem, its leading sleep disorder drugs, remain key revenue drivers, supporting the company's upward trajectory.
Jazz Pharmaceuticals currently holds a market cap of $11.64 billion, with its stock showing resilience near $185. Analysts anticipate further gains, backed by strong earnings and sector growth. The company's focus on neuroscience and oncology positions it well for continued expansion in the coming years.
